186
Participants
Start Date
July 31, 2016
Primary Completion Date
July 31, 2017
Study Completion Date
January 31, 2019
Guardant360
Cell-free circulating tumor DNA (cfDNA) targeted next-generation sequencing (NGS) panel.
H. Can Ruti, Badalona
Dexeus, Barcelona
H. del Mar, Barcelona
H. Sant Pau, Barcelona
H. Vall Hebrón, Barcelona
ICO Bellvitge, L'Hospitalet de Llobregat
H. Arnau de Vilanova, Valencia
Collaborators (1)
Guardant Health, Inc.
INDUSTRY
MedSIR
OTHER